Repository logo
 
Publication

New Prospects for the Management of Cardiovascular Effects of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia

2019Journal article Open access
Simple item page
dc.contributor.authorAlmeida, A
dc.contributor.authorAlmeida, A
dc.contributor.authorMelo, T
dc.contributor.authorGuerra, L
dc.contributor.authorLopes, L
dc.contributor.authorRibeiro, P
dc.contributor.authorDuarte, M
dc.contributor.authorMota, A
dc.contributor.authorFontes-Carvalho, R
dc.date.accessioned2019-12-09T16:10:14Z
dc.date.available2019-12-09T16:10:14Z
dc.date.issued2019
dc.description.abstractThe use of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia has significantly altered the prognosis of this disease, enabling close to normal life expectancy. Despite their undeniable benefits, the use of TKIs is associated with an increased risk of side effects on the cardiovascular system, particularly of atherothrombotic events. It is therefore necessary to understand and prevent the adverse effects of these drugs, in order to enable antileukemic therapy to continue and to minimize patients' toxic exposure. This multidisciplinary consensus document, developed through a collaboration between hematologists and cardiologists, aims to review the cardiovascular toxicity associated with various TKIs and to establish recommendations for the follow-up of these patients. Measures are also proposed for the assessment and reduction of cardiovascular risk in these patients and referral criteria, and relevant drug interactions are discussed.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationRev Port Cardiol. 2019 Jan;38(1):1-9.pt_PT
dc.identifier.doi10.1016/j.repc.2017.10.013pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/3383
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevier Españapt_PT
dc.subjectHSAC HEMpt_PT
dc.subjectAntineoplastic Agents/adverse effectspt_PT
dc.subjectCardiotoxicitypt_PT
dc.subjectCardiovascular Diseases/chemically inducedpt_PT
dc.subjectCardiovascular Diseases/prevention & controlpt_PT
dc.subjectCardiovascular System/drug effectspt_PT
dc.subjectLeukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
dc.subjectProtein Kinase Inhibitors/adverse effects
dc.subjectProtein-Tyrosine Kinases/antagonists & inhibitors
dc.titleNew Prospects for the Management of Cardiovascular Effects of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemiapt_PT
dc.title.alternativeNovas Perspetivas Para a Abordagem dos Efeitos Cardiovasculares dos Inibidores da Torosinacinase em Doentes com Leucemia Mieloide Crónicapt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage9pt_PT
oaire.citation.issue1pt_PT
oaire.citation.startPage1pt_PT
oaire.citation.titleRevista Portuguesa de Cardiologiapt_PT
oaire.citation.volume38pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
RPC 2019.pdf
Size:
500.55 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

HEM - Artigos